About Lamark Biotech
Lamark Biotech is a Healthcare company based in Bengaluru (India) founded in 2018 by Vaibhav Bhatia. Lamark Biotech has raised $982.84 thousand across 3 funding rounds from investors including BioAngels, VIT-TBI and Indian Angel Network. Lamark Biotech was last valued at $870.54 thousand in March 2021. Its chief executive, as recorded, is Vaibhav Bhatia. Its Indian entity Lamark Biotech Private Limited reported revenue of ₹3.26 Cr. Lamark Biotech offers products and services including Proteostrong Technology and Drug Pipeline. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Provider of therapeutic proteins for treating diabetes and other diseases. The company develops its proprietary molecular medicine, therapeutic proteins, gene therapies, and cell therapies based products. The flagship product of the company is InsulinStrong which is a crystalline form of recombinant human Insulin and is refrigeration-independent used for treating type one diabetes.
- Headquarters Bengaluru, India
- Founders Vaibhav Bhatia
- SectorsHealthcare
- Phone•••• ••••
- Website lamarkbiotech.com
- Social LinkedIn X Instagram
- Legal Name Lamark Biotech Private Limited
- Date of Incorporation 30 Oct, 2018
- Jurisdiction Ahmedabad, Gujarat, India
- Annual Revenue₹3.26 Cr
FY 2025 · +6928% YoY
- Net Loss-₹98.4 Lakh
FY 2025 · -30% margin
- EBITDA-₹88.9 Lakh
FY 2025 · -27% margin
- Total Equity Funding$982.84K (USD)
in 3 rounds
- Latest Funding Round$758.6K (USD), Seed
Jul 2025
- InvestorsBioAngels
& 7 more
Associated legal entities of Lamark Biotech
Lamark Biotech operates through Lamark Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Lamark Biotech Private Limited CIN U74999GJ2018PTC105007 | Active | 30 Oct 2018 | Ahmedabad, Gujarat | ₹3.3 Cr | 1,234 | 3 | View details |
Products & Services of Lamark Biotech
Lamark Biotech offers a comprehensive portfolio of products and services, including Proteostrong Technology and Drug Pipeline.
Technology for developing biologics and enhancing drug innovation
Pipeline of formulations targeting global health challenges
Funding Insights of Lamark Biotech
Lamark Biotech has successfully raised a total of $982.84K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $758.6 thousand completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $982,841
- Total Rounds 3
- Last Round Seed — $758,596
- First Round $41,255
(Mar 2021)
- Investors Count 8
All 3 funding rounds of Lamark Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $758,596 | Seed | – | Indian Angel Network | |
| Apr 2023 | $182,990 | Seed | – | IKP Knowledge Park | |
| Mar 2021 | $41,255 | Seed | $870,537 | VIT-TBI | – |
Last known valuation $870,537 (Mar 2021). 8 investors in total: 5 institutional and 3 angel.
Investors in Lamark Biotech
Lamark Biotech has secured backing from 8 investors, including venture fund and angel investors. Prominent investors backing the company include BioAngels, VIT-TBI and Indian Angel Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Technology business incubation and support services for innovators are provided in India. | 2003 | vittbi.com | Vellore, India | |
Angel investor network investing in early-stage startups | iangroup.vc | Delhi, India | ||
Investment and support platform for biotech and related startups in India. | 2022 | bioangels.vc | Delhi, India | |
| ikpknowledgepark.com | ||||
| venturecenter.co.in | ||||
VT Vinayender Tulla | unknown_53387ae140194f3ba | |||
NR Nita Roy | unknown_9df4bfa2a2574b2a9 | |||
VK Venkataraman KNK | Angel investor, ex-entrepreneur, focused on early-stage Indian startups | unknown_783bfcf86c5647cd9 |
Investor details for Lamark Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Lamark Biotech Private Limited (Lamark Biotech)
Lamark Biotech Private Limited is the primary company behind Lamark Biotech. The board of Lamark Biotech Private Limited currently have 3 directors; the longest-serving is Rajat Bhatia, appointed in 2018.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rajat Bhatia DIN 08269676 | Director | 30 Oct 2018 | 8 yrs | Lamark Biotech Private Limited |
| Inderkumar Santram Bhatia DIN 08269675 | Director | 30 Oct 2018 | 8 yrs | Lamark Biotech Private Limited |
| Vaibhav Bhatia DIN 08585341 | Director | 15 Oct 2019 | 7 yrs | Lamark Biotech Private Limited |
People of Lamark Biotech
1 people are tracked at Lamark Biotech (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder & CEO | Leadership |
Complete people profiles for Lamark Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Lamark Biotech
Figures of Lamark Biotech Private Limited, the primary company behind Lamark Biotech, for FY 2025. Revenue was ₹3.26 Cr (+6928% year on year). Net loss was -₹98.4 Lakh (-30% margin). EBITDA was -₹88.9 Lakh (-27% margin). Revenue has grown at a compounded annual rate of +179% over three years and +320% over five years.
- ₹3.26 CrRevenue · FY 2025 · +6928% YoY
- -₹98.4 LakhNet loss · -30% margin
- -₹88.9 LakhEBITDA · -27% margin
- ₹59,150Paid-up capital
- 1,234Employees (provident fund records)
- +179%Revenue CAGR, 3 years
- +320%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Lamark Biotech Private Limited are on its company page.
Detailed financial statements for Lamark Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Lamark Biotech
3 dated milestones of Lamark Biotech across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Lamark Biotech is founded.
- Funding First funding round of $41K.
- Funding Latest funding round, Seed, of $759K.
Web traffic of Lamark Biotech
The website of Lamark Biotech (lamarkbiotech.com) receives about 2.8K visits a month.
- Monthly visits2.8K
▼ 47.4% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lamark Biotech
Complete news archive for Lamark Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lamark Biotech
Lamark Biotech was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Lamark Biotech is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Vaibhav Bhatia is the CEO of Lamark Biotech, as recorded in our data. They have also founded this company.
Lamark Biotech is a funded company, having raised a total of $982.84K across 3 funding rounds to date. The company's 1st funding round was a Seed of $41.26K, raised on Mar 2021.
The primary company behind Lamark Biotech, Lamark Biotech Private Limited, reported revenue of ₹3.26 Cr for FY 2025, up 6928% year on year.
Provider of therapeutic proteins for treating diabetes and other diseases. The company develops its proprietary molecular medicine, therapeutic proteins, gene therapies, and cell therapies based products. The flagship product of the company is InsulinStrong which is a crystalline form of recombinant human Insulin and is refrigeration-independent used for treating type one diabetes.
Lamark Biotech offers Proteostrong Technology and Drug Pipeline.
Lamark Biotech has 8 investors. Key investors include BioAngels, VIT-TBI, Indian Angel Network, Vinayender Tulla, and Nita Roy.
The valuation of Lamark Biotech is $870.54K as of Mar 2021.
Lamark Biotech operates through Lamark Biotech Private Limited.
The legal entities of Lamark Biotech currently have 3 directors, including Vaibhav Bhatia, Rajat Bhatia, Inderkumar Santram Bhatia.